妊娠期阴道黄体酮的药代动力学
本研究为前瞻性研究,纳入6例低危单胎妊娠孕妇(孕18 0/7至23 6/7周),单次阴道给予200 mg微粒化黄体酮后系列采血。结果显示血清黄体酮中位峰值54 ng/mL、中位达峰时间12小时,较基线中位升高11 ng/mL(中位百分比升高24%),但无明确消除相,个体间变异显著;作者认为血清黄体酮不适合用于建立妊娠期阴道黄体酮的药代动力学或给药方案。
要点
- 低危单胎妊娠孕妇单次阴道200 mg微粒化黄体酮后,血清黄体酮较基线仅有限上升。
- 中位峰值54 ng/mL、中位达峰时间12小时,无明确消除相,个体间变异显著。
- 作者认为血清黄体酮不太适合用于建立妊娠期阴道黄体酮的药代动力学或给药方案。
核心结论
- 与非妊娠个体不同,妊娠个体阴道给予黄体酮对全身暴露影响很小。
- 血清黄体酮较基线仅有有限的上升趋势,个体间变异显著。
- 血清黄体酮不太可能成为建立妊娠期阴道黄体酮药代动力学或给药方案的良好指标。
研究设计与样本
- 前瞻性研究,纳入6例低危单胎妊娠孕妇,孕18 0/7至23 6/7周,体重指数20-40。
- 排除标准包括当前阴道炎、巴氏涂片异常、处方药使用、宫颈长度≤25 mm、既往早产及黄体酮禁忌。
- 参与者单次接受200 mg微粒化阴道黄体酮,给药后0至12小时每2小时及24小时评估血清黄体酮。
- 主要结局为血清黄体酮的浓度/时间曲线。
主要发现
- 母亲年龄中位数27岁(范围21.5-33.3),体重指数中位数26.5 kg/m2(范围23.3-29.0),孕周中位数22.9周(范围21.0-23.4)。
- 基线血清黄体酮中位数47 ng/mL(范围40-52),峰值浓度中位数54 ng/mL(范围48-68),达峰时间中位数12小时(范围4-15)。
- 峰值浓度较基线中位变化为11 ng/mL,四分位距2-22;中位百分比变化为升高24%(四分位距4%-53%)。
- 无明确消除相,曲线下面积中位数112 ng*h/mL,四分位距-43至239。
局限性
- 样本量为6例。
- 血清黄体酮较基线上升趋势有限且个体间变异显著。
- 无明确消除相。
- 作者结论认为血清黄体酮不太可能成为建立妊娠期阴道黄体酮药代动力学或给药方案的良好指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Characterization of pharmacokinetics is lacking for vaginal progesterone in pregnancy. Dosing of vaginal progesterone for preterm birth prevention has been empirical. Owing to pregnancy-related changes in vaginal and uterine blood flow, hepatic metabolism, renal clearance, and endogenously elevated serum progesterone, studies outside of pregnancy may not be applicable. The lack of the pharmacokinetics profile of vaginally administered progesterone in pregnancy limits the ability to define the exposure-response relationship needed to optimize dosing, which has implications for its use in research and clinical care regarding management of short cervix, prevention of recurrent preterm birth, and prevention of recurrent miscarriage. OBJECTIVE: This was a study to establish the feasibility of using serum progesterone to establish basic pharmacokinetic parameters of vaginal progesterone in pregnancy for preterm birth prevention. STUDY DESIGN: This is a prospective study of 6 low-risk singletons at 18 0/7 to 23 6/7 weeks' gestation with body mass index 20-40. Exclusion criteria were current vaginitis, abnormal Pap smear, prescription medication use, cervical length ≤25 mm, prior preterm birth, and contraindication to progesterone. Participants received a single dose of 200 mg micronized vaginal progesterone and serum progesterone levels were evaluated every 2 hours from 0 to 12 hours and then 24 hours post dose. Primary outcome was concentration/time profile of serum progesterone. RESULTS: Median (range) maternal age was 27 (21.5-33.3) years, median body mass index was 26.5 (23.3-29.0) kg/m2, and median gestational age was 22.9 (21.0-23.4) weeks. Median baseline serum progesterone was 47 (40-52) ng/mL, median peak concentration was 54 (48-68) ng/mL, and median time to peak was 12 (4-15) hours. There was a trend in rising serum progesterone over baseline with a median change in peak concentration of 11 ng/mL and interquartile range of 2-22. Median percent change from baseline was an increase by 24% (interquartile range, 4%-53%). However, there was no clear elimination phase and the median area under the curve was 112 ng*h/mL with an interquartile range of -43 to 239. CONCLUSION: Unlike in nonpregnant individuals, administration of vaginal progesterone in pregnant individuals only minimally impacts systemic exposure. There is a limited trend of rising serum progesterone over baseline levels, with significant inter-individual variability. Serum progesterone is unlikely to be a good candidate for establishing pharmacokinetics or dosing of vaginal progesterone in pregnancy for preterm birth prevention.
引用
- Boelig RC, Zuppa AF, Kraft WK, et al. Pharmacokinetics of vaginal progesterone in pregnancy. Am J Obstet Gynecol. 2019. PMID: 31211965. doi:10.1016/j.ajog.2019.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。